Cargando…
Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis
BACKGROUND: Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with poor prognosis, conferring up to a 10-fold increase in mortality in patients with sarcoidosis, but the actual prevalence of SAPH is unknown. METHODS: The PubMed, Embase, and Cochrane Library databases were systematic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801498/ https://www.ncbi.nlm.nih.gov/pubmed/35111830 http://dx.doi.org/10.3389/fcvm.2021.809594 |
_version_ | 1784642474042458112 |
---|---|
author | Zhang, Shijie Tong, Xiang Zhang, Tianli Wang, Dongguang Liu, Sitong Wang, Lian Fan, Hong |
author_facet | Zhang, Shijie Tong, Xiang Zhang, Tianli Wang, Dongguang Liu, Sitong Wang, Lian Fan, Hong |
author_sort | Zhang, Shijie |
collection | PubMed |
description | BACKGROUND: Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with poor prognosis, conferring up to a 10-fold increase in mortality in patients with sarcoidosis, but the actual prevalence of SAPH is unknown. METHODS: The PubMed, Embase, and Cochrane Library databases were systematically searched for epidemiological studies reporting the prevalence of SAPH up to July 2021. Two reviewers independently performed the study selection, data extraction, and quality assessment. Studies were pooled using random-effects meta-analysis. RESULTS: This meta-analysis included 25 high-quality studies from 12 countries, with a pooled sample of 632,368 patients with sarcoidosis. The prevalence of SAPH by transthoracic echocardiography in Europe, the United States and Asia was 18.8% [95% confidence interval (CI): 11.1–26.5%], 13.9% (95% CI: 5.4–22.4%) and 16.2% (95% CI: 7.1–25.4%) separately, and the overall pooled prevalence was 16.4% (95%CI: 12.2–20.5%). By right heart catheterization (RHC), the pooled prevalence of SAPH was 6.4% (95% CI: 3.6–9.1%) in general sarcoidosis population, and subgroup analyses showed that the prevalence of SAPH was 6.7% (95% CI: 2.4–11.0%) in Europe and 8.6% (95% CI: −4.1 to 21.3%) in the United States. Further, the prevalence of pre-capillary PH was 6.5% (95% CI: 2.9–10.2%). For the population with advanced sarcoidosis, the pooled prevalence of SAPH and pre-capillary PH by RHC was as high as 62.3% (95% CI: 46.9–77.6%) and 55.9% (95% CI: 20.1–91.7%), respectively. Finally, the pooled prevalence of SAPH in large databases with documented diagnoses (6.1%, 95% CI: 2.6–9.5%) was similar to that of RHC. Substantial heterogeneity across studies was observed for all analyses (I(2) > 80%, P < 0.001). CONCLUSIONS: The sarcoidosis population has a relatively low burden of PH, mainly pre-capillary PH. However, as the disease progresses to advanced sarcoidosis, the prevalence of SAPH increases significantly. |
format | Online Article Text |
id | pubmed-8801498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88014982022-02-01 Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis Zhang, Shijie Tong, Xiang Zhang, Tianli Wang, Dongguang Liu, Sitong Wang, Lian Fan, Hong Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with poor prognosis, conferring up to a 10-fold increase in mortality in patients with sarcoidosis, but the actual prevalence of SAPH is unknown. METHODS: The PubMed, Embase, and Cochrane Library databases were systematically searched for epidemiological studies reporting the prevalence of SAPH up to July 2021. Two reviewers independently performed the study selection, data extraction, and quality assessment. Studies were pooled using random-effects meta-analysis. RESULTS: This meta-analysis included 25 high-quality studies from 12 countries, with a pooled sample of 632,368 patients with sarcoidosis. The prevalence of SAPH by transthoracic echocardiography in Europe, the United States and Asia was 18.8% [95% confidence interval (CI): 11.1–26.5%], 13.9% (95% CI: 5.4–22.4%) and 16.2% (95% CI: 7.1–25.4%) separately, and the overall pooled prevalence was 16.4% (95%CI: 12.2–20.5%). By right heart catheterization (RHC), the pooled prevalence of SAPH was 6.4% (95% CI: 3.6–9.1%) in general sarcoidosis population, and subgroup analyses showed that the prevalence of SAPH was 6.7% (95% CI: 2.4–11.0%) in Europe and 8.6% (95% CI: −4.1 to 21.3%) in the United States. Further, the prevalence of pre-capillary PH was 6.5% (95% CI: 2.9–10.2%). For the population with advanced sarcoidosis, the pooled prevalence of SAPH and pre-capillary PH by RHC was as high as 62.3% (95% CI: 46.9–77.6%) and 55.9% (95% CI: 20.1–91.7%), respectively. Finally, the pooled prevalence of SAPH in large databases with documented diagnoses (6.1%, 95% CI: 2.6–9.5%) was similar to that of RHC. Substantial heterogeneity across studies was observed for all analyses (I(2) > 80%, P < 0.001). CONCLUSIONS: The sarcoidosis population has a relatively low burden of PH, mainly pre-capillary PH. However, as the disease progresses to advanced sarcoidosis, the prevalence of SAPH increases significantly. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8801498/ /pubmed/35111830 http://dx.doi.org/10.3389/fcvm.2021.809594 Text en Copyright © 2022 Zhang, Tong, Zhang, Wang, Liu, Wang and Fan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Zhang, Shijie Tong, Xiang Zhang, Tianli Wang, Dongguang Liu, Sitong Wang, Lian Fan, Hong Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis |
title | Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis |
title_full | Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis |
title_fullStr | Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis |
title_short | Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis |
title_sort | prevalence of sarcoidosis-associated pulmonary hypertension: a systematic review and meta-analysis |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801498/ https://www.ncbi.nlm.nih.gov/pubmed/35111830 http://dx.doi.org/10.3389/fcvm.2021.809594 |
work_keys_str_mv | AT zhangshijie prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis AT tongxiang prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis AT zhangtianli prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis AT wangdongguang prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis AT liusitong prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis AT wanglian prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis AT fanhong prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis |